7 December 2015 - Gilead Sciences Canada, Inc. today announced that Health Canada has issued a Notice of Compliance for Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. Genvoya is the first TAF-based regimen to receive marketing authorization in Canada.

For more details, go to: http://www.businesswire.com/news/home/20151207005474/en/Health-Canada-Issues-Notice-Compliance-Gilead’s-Single